This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Shanghai Zelgen Pharma.tech Co., Ltd., Suzhou Zelgen Biopharmaceuticals Co., Ltd.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: Peizhong Ni: Innovator in KRAS Inhibition
Introduction
Peizhong Ni is a notable inventor based in Shanghai, China. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of compounds that target KRAS, a critical protein involved in cancer progression. His innovative work has the potential to impact cancer treatment significantly.
Latest Patents
Peizhong Ni holds a patent for "Cycloalkyl and hetero-cycloalkyl inhibitors, preparation methods therefor, and use thereof." This patent describes compounds with a structure represented by formula (I). The invention details preparation methods for these compounds and their application as KRAS inhibitors. The compounds exhibit an excellent ability to selectively inhibit KRAS, along with improved pharmacodynamic and pharmacokinetic performance, while also reducing toxic side effects. He has 1 patent to his name.
Career Highlights
Throughout his career, Peizhong Ni has worked with prominent companies in the biopharmaceutical sector. Notably, he has been associated with Suzhou Zelgen Biopharmaceuticals Co., Ltd. and Shanghai Zelgen Pharma Technology Co., Ltd. His work in these organizations has contributed to advancements in drug development and therapeutic solutions.
Collaborations
Peizhong Ni has collaborated with several professionals in his field, including Binhua Lv and Dawei Cui. These collaborations have fostered innovation and enhanced the research and development of new therapeutic compounds.
Conclusion
Peizhong Ni's contributions to the field of biopharmaceuticals, particularly in KRAS inhibition, highlight his role as an influential inventor. His work continues to pave the way for advancements in cancer treatment and therapeutic development.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile